Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ARQT
ARQT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARQT News
Tejara Capital Fully Exits Arcutis Biotherapeutics Stake
Feb 06 2026
Fool
Arcutis' ZORYVE Revenue Reaches $244.6M in 2025 YTD, Anticipates $470M for 2026
Jan 06 2026
NASDAQ.COM
Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming
Dec 31 2025
NASDAQ.COM
Suvretta Capital Reduces Arcutis Stake by $35.78 Million
Dec 23 2025
Fool
Suvretta Capital Management Sells Nearly 1.1M ARQT Shares, Reducing Position by $35.78M
Dec 23 2025
NASDAQ.COM
Zacks Industry Forecast for Arcutis, Amicus, and ANI
Dec 18 2025
NASDAQ.COM
5 Biotech Stocks to Keep an Eye On for Possible Growth
Dec 17 2025
NASDAQ.COM
Evaluating Arcutis Biotherapeutics Following a 99% Year-to-Date Increase and Varied Valuation Indicators
Dec 14 2025
Yahoo Finance
This Biotech Stock Might Alleviate Your Portfolio's Struggles
Dec 14 2025
NASDAQ.COM
Reasons to Consider Arcutis Biotherapeutics, Inc. (ARQT) as a Strong Momentum Stock: Is It Time to Buy?
Dec 10 2025
NASDAQ.COM
Arcutis Appoints Amit Munshi to Board, Strengthening Leadership for Growth
Dec 08 2025
Globenewswire
Arcutis Appoints Amit Munshi to Board, Strengthening Leadership for ZORYVE Commercialization
Dec 08 2025
Newsfilter
PRAX Shares Surge 520% in Just 3 Months: Key Information You Should Be Aware Of
Dec 08 2025
NASDAQ.COM
Incyte's Treatment for Rare Blood Cancer Receives Breakthrough Designation from FDA
Dec 08 2025
NASDAQ.COM
Mizuho Continues to Endorse Arcutis Biotherapeutics (ARQT) with an Outperform Rating
Nov 29 2025
NASDAQ.COM
Mizuho Reaffirms Outperform Rating for Arcutis Biotherapeutics and Increases Price Target to $37
Nov 28 2025
Benzinga
Show More News
